Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 - PubMed
8 days ago
- #immunotherapy
- #gastroesophageal-cancer
- #long-term-survival
- Nivolumab plus chemotherapy shows sustained overall survival (OS) and progression-free survival (PFS) benefits in patients with PD-L1 CPS ≥5 after 5 years.
- Five-year OS rates were 16% for nivolumab plus chemotherapy vs. 6% for chemotherapy alone in PD-L1 CPS ≥5 patients.
- Objective response rate was higher with nivolumab plus chemotherapy (58%) compared to chemotherapy alone (46%).
- Survival benefits were maintained across different PD-L1 expression levels (CPS ≥1, CPS ≥10) and all randomized patients.
- Grade 3/4 treatment-related adverse events occurred in 60% of nivolumab plus chemotherapy patients vs. 45% with chemotherapy alone.
- No new safety concerns were identified after long-term follow-up.
- Nivolumab plus chemotherapy is reinforced as a standard first-line treatment for PD-L1 positive gastroesophageal adenocarcinoma.